SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data At Epilepsy Pipeline Conference
6/5/2014 10:00:28 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics (SAGE), a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).
Help employers find you! Check out all the jobs and post your resume.
comments powered by